Expert Review of Cardiovascular Therapy最新文献

Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective.

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-02-12 DOI: 10.1080/14779072.2025.2463332

Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas

{"title":"Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective.","authors":"Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas","doi":"10.1080/14779072.2025.2463332","DOIUrl":"10.1080/14779072.2025.2463332","url":null,"abstract":"Background: We present an analysis of cardiovascular-related deaths specific to hematological cancer patients in the United States from 1999 to 2020, examining trends in relation to age, gender, and type of hematological cancer.Research design and methods: Utilizing the Multiple Cause of Death databases, our research included 88,146 decedents with cardiovascular primary cause of death and with hematologic disease. We determined the percentage of cardiovascular deaths associated with each disease category. Furthermore, we developed age-adjusted mortality rates, categorizing them based on sex, age, race, Latino origin, and the type of hematological cancer.Results: Between 1999 and 2020, there was a decreasing temporal trend in overall cardiovascular mortality for lymphoma, leukemia and multiple myeloma (-38.8% -31.8% & -29.4%). The most common cardiovascular mortality cause in the hematological malignancy population was ischemic heart disease, followed by cerebrovascular disease (53.4%, 20.2%). African American, Asian, and White patients showed decreasing for overall CV death for all hematological malignancies, with African American subgroups showing the lowest mortality reduction over time (AAMR: -26.8%, -41.2%, -33.3%). However, hypertension mortality increased for most racial groups.Conclusions: Over the last 2 decades, the rate of cardiovascular mortality amongst patients with underlying hematological malignancy has decreased.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The gut microbiota and its role in the development of cardiovascular disease.

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-02-10 DOI: 10.1080/14779072.2025.2463366

Carlos Escobar, Xavier Aldeguer, David Vivas, Sergio Manzano Fernández, Eva Gonzalez Caballero, Ana Garcia Martín, Vivencio Barrios, Román Freixa-Pamias

{"title":"The gut microbiota and its role in the development of cardiovascular disease.","authors":"Carlos Escobar, Xavier Aldeguer, David Vivas, Sergio Manzano Fernández, Eva Gonzalez Caballero, Ana Garcia Martín, Vivencio Barrios, Román Freixa-Pamias","doi":"10.1080/14779072.2025.2463366","DOIUrl":"10.1080/14779072.2025.2463366","url":null,"abstract":"Introduction: The pathophysiology of cardiovascular diseases encompasses a complex interplay of genetic and environmental risk factors. Even if traditional risk factors are treated to target, there remains a residual risk.Areas covered: This manuscript reviews the potential role of gut microbiota in the development of cardiovascular disease, and as potential target. A systematic search was conducted until 30 October 2024 on PubMed (MEDLINE), using the MeSH terms [Gut microbiota] + [Dysbiosis] + [Cardiovascular] + [TMAO] + [bile acids] + [short-chain fatty acids].Expert opinion: The term dysbiosis implies changes in equilibrium, with modifications in the composition and functionality of microbiota and a series of additional factors: reduced diversity and uniformity of microorganisms; reduced short-chain fatty acid-producing bacteria; increased gut permeability; release of metabolites, such as trimethylamine N-oxide, betaine, phenylalanine, tryptophan-kynurenine, phenylacetylglutamine, and lipopolysaccharides; and reduced secondary bile acid excretion, leading to inflammation, oxidative stress, and endothelial dysfunction and facilitating the onset of pathological conditions, including obesity, hypertension, diabetes, atherosclerosis, and heart failure. Attempts to restore gut microbiota balance through different interventions, mainly changes in diet, have been shown to positively affect individual components and metabolites and reduce the risk of cardiovascular disease. In addition, probiotics and prebiotics are potentially useful. Fecal microbiota transplantation is a promising therapy.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is transthyretin amyloid cardiomyopathy heading towards losing its rare disease classification?

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-02-10 DOI: 10.1080/14779072.2025.2463333

Anouk Achten, Steven A Muller, Peter-Paul Zwetsloot, Michelle Michels, Peter van der Meer, Hans L A Nienhuis, Manon G van der Meer, Vanessa P M van Empel, Marish I F J Oerlemans, Christian Knackstedt

引用次数: 0

Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence).

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-02-07 DOI: 10.1080/14779072.2025.2464180

Manuel Anguita, Francisco Marín, Javier Soto, Susana Fernández de Cabo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés

{"title":"Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence).","authors":"Manuel Anguita, Francisco Marín, Javier Soto, Susana Fernández de Cabo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés","doi":"10.1080/14779072.2025.2464180","DOIUrl":"https://doi.org/10.1080/14779072.2025.2464180","url":null,"abstract":"Objective: To analyze the cost-effectiveness of apixaban in the prevention ofstroke in adult patients with non-valvular atrial fibrillation (NVAF), comparedto other direct-acting oral anticoagulants (dabigatran, rivaroxaban, edoxaban)and the vitamin K antagonist acenocoumarol, based on data on effectiveness inclinical practice in Spain obtained in the FANTASIIA study.Research design and methods: A probabilistic Markov economic model (second-order Monte Carlosimulation) was performed to analyze the costs and utilities (quality-adjustedlife years, QALYs) associated with the compared treatments, according to thedifferent probabilities of stroke, major bleeding and death observed inFANTASIIA.Results: The cost per QALY gained in the patient treated with apixabanversus comparators ranged from €2,919 to €7,462. The probability of apixabanbeing cost-effective ranges from 91.1% (vs dabigatran 150 mg), 97.8% (vsdabigatran 110 mg), and 100% (vs. rivaroxaban, edoxaban, and acenocoumarol).Conclusions: Based on the results of the FANTASIIA study, apixaban is acost-effective treatment (below a willingness to pay of €25,000 per QALYgained) compared to dabigatran, rivaroxaban, edoxaban, and acenocoumarol intreating patients with NVAF.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician's best option for HIV patients?

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-02-07 DOI: 10.1080/14779072.2025.2463348

Francisco Akira Malta Cardozo, Luciana Dornfeld Bichuette, Bruno Caramelli

{"title":"Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician's best option for HIV patients?","authors":"Francisco Akira Malta Cardozo, Luciana Dornfeld Bichuette, Bruno Caramelli","doi":"10.1080/14779072.2025.2463348","DOIUrl":"10.1080/14779072.2025.2463348","url":null,"abstract":"Introduction: People living with HIV (PLHIV) are at higher risk of cardiovascular disease (CVD), and dyslipidemia is a prevalent comorbidity that requires effective treatment. Limitations for the use of statins such as drug interactions and adverse effects highlight the need for alternative therapies.Areas covered: This review evaluates the role of PCSK9 inhibitors in reducing cardiovascular risk in PLHIV with dyslipidemia. We analyzed studies available on PUBMED, using keywords HIV, dyslipidemia, PCSK9 inhibitors, and statin intolerance. We discuss the mechanisms underlying increased cardiovascular risk, limitations of statins, including a recent study using PCSK9 inhibitors. Evolocumab significantly reduced LDL-C levels by 56.9% in PLHIV, with 72.5% of patients achieving ≥50% LDL-C reduction. The trial confirmed the drug's safety. Additionally, PCSK9 inhibitors demonstrated reductions in lipoprotein(a) and inflammatory markers.Expert opinion: PCSK9i present a promising option for lipid management in PLHIV, especially in statin-intolerant individuals or those with residual risk despite statin therapy. Additional non-statin therapies targeting adverse lipid profiles, including low HDL-C, high triglycerides, and lipoprotein(a), are under development. Combined with advancements in antisense oligonucleotides (ASOs) and siRNA technologies, they hold promise for transforming the treatment of dyslipidemia and cardiovascular disease in PLHIV.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk scoring systems for early prediction of short-term mortality in resuscitated out-of-hospital cardiac arrest patients. 院外心脏骤停复苏患者短期死亡率早期预测的风险评分系统。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-04 DOI: 10.1080/14779072.2025.2449899

Tharusan Thevathasan, Ulf Landmesser, Anne Freund, Janine Pöss, Carsten Skurk, Holger Thiele, Steffen Desch

{"title":"Risk scoring systems for early prediction of short-term mortality in resuscitated out-of-hospital cardiac arrest patients.","authors":"Tharusan Thevathasan, Ulf Landmesser, Anne Freund, Janine Pöss, Carsten Skurk, Holger Thiele, Steffen Desch","doi":"10.1080/14779072.2025.2449899","DOIUrl":"10.1080/14779072.2025.2449899","url":null,"abstract":"Introduction: Out-of-hospital cardiac arrest (OHCA) is a critical condition associated with high mortality rates and neurological impairment among survivors. In comatose OHCA patients who achieve return of spontaneous circulation, early risk stratification is important to inform treatment pathways and potentially improve outcomes. A range of prognostic tools have been developed to predict survival and neurological recovery. Each tool incorporates a unique combination of clinical, biochemical and physiological markers.Areas covered: This review article evaluates the required clinical data, predictive performances and practical applicability of major risk scores. A literature review was conducted in PubMed and Embase for studies published between January 2000 and October 2024. The review emphasizes the variability in discriminative power among the selected scores, with some models offering high sensitivity and specificity in outcome prediction, while others prioritize simplicity and accessibility.Expert opinion: Despite the advancements of these tools, limitations persist in data dependency and the clinical adaptability, highlighting areas for future improvement. Integrating artificial intelligence and real-time analytics could enhance predictive accuracy, offering dynamic prognostic capabilities that adapt to individual patient trajectories. This evolution must be grounded in ethical considerations to ensure predictive technologies complement rather than replace clinical judgment, balancing technology's potential with the complexities of individualized patient care.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and efficacy of cerebral embolic protection systems in transcatheter aortic valve replacement: a systematic review and meta-analysis. 经导管主动脉瓣置换术中脑栓塞保护系统的安全性和有效性：系统回顾和荟萃分析。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-12-27 DOI: 10.1080/14779072.2024.2445256

Mazhed Kheyrbek, Sam Alsabti, Shailesh Niroula, Ela Ahmad, Mustapha Choucair, Unnati Bhatia, Adam Wernette, Karan Chhabra, Kateryna Strubchevska, Ivan Hanson, Alexandra Halalau

{"title":"Safety and efficacy of cerebral embolic protection systems in transcatheter aortic valve replacement: a systematic review and meta-analysis.","authors":"Mazhed Kheyrbek, Sam Alsabti, Shailesh Niroula, Ela Ahmad, Mustapha Choucair, Unnati Bhatia, Adam Wernette, Karan Chhabra, Kateryna Strubchevska, Ivan Hanson, Alexandra Halalau","doi":"10.1080/14779072.2024.2445256","DOIUrl":"10.1080/14779072.2024.2445256","url":null,"abstract":"Background: Stroke is a potential complication of Transcatheter Aortic Valve Replacement (TAVR). Recent trials evaluating Cerebral Embolic Protection Systems (CEPS) to reduce the incidence of stroke after TAVR have been conflicting.Methods: Multiple databases were searched for studies comparing TAVR with or without CEPS and that reported on the primary outcome of periprocedural stroke. Two authors individually screened the titles, the abstracts and the full texts using Covidence. Risk of bias was assessed using Cochrane's ROB-2 and ROBINS-I tools.Results: A total of 15 studies (3 randomized controlled trials, 7 national registries, and 5 cohort studies) met the eligibility criteria and were included in our review. CEPS was associated with lower rates of periprocedural stroke [OR 0.71 (95% CI 0.55, 0.93) p = 0.012], as well as lower rates of mortality [OR 0.60 (95% CI 0.49, 0.74) p < 0.001]. There was no significant difference between the two groups in the incidence of acute kidney injury [OR 0.91 (95% CI 0.82, 1.01) p = 0.087], major vascular complications [OR 0.97 (95% CI 0.83, 1.14) p = 0.734], and major life-threatening bleeding [OR 0.89 (95% CI 0.73, 1.07) p = 0.222].Conclusions: Our findings suggest that the use of CEPS in TAVR is associated with a lower risk of periprocedural stroke and mortality.Registration: The PROSPERO identification number is CRD42022374055.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing outcomes from cardiac resynchronization therapy: what do recent data and insights say? 优化心脏再同步化治疗的结果：最近的数据和见解说了什么？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-12-25 DOI: 10.1080/14779072.2024.2445246

Felicity de Vere, Nadeev Wijesuriya, Sandra Howell, Mark K Elliott, Vishal Mehta, Nilanka N Mannakkara, Marina Strocchi, Steven A Niederer, Christopher A Rinaldi

{"title":"Optimizing outcomes from cardiac resynchronization therapy: what do recent data and insights say?","authors":"Felicity de Vere, Nadeev Wijesuriya, Sandra Howell, Mark K Elliott, Vishal Mehta, Nilanka N Mannakkara, Marina Strocchi, Steven A Niederer, Christopher A Rinaldi","doi":"10.1080/14779072.2024.2445246","DOIUrl":"10.1080/14779072.2024.2445246","url":null,"abstract":"Introduction: Cardiac Resynchronization Therapy (CRT) is an effective treatment for heart failure (HF) in approximately two-thirds of recipients, with a third remaining CRT 'non-responders.' There is an increasing body of evidence exploring the reasons behind non-response, as well as ways to preempt or counteract it.Areas covered: This review will examine the most recent evidence regarding optimizing outcomes from CRT, as well as explore whether traditional CRT indeed remains the best first-line therapy for electrical resynchronization in HF. We will start by discussing methods of preempting non-response, such as refining patient selection and procedural technique, before reviewing how responses can be optimized post-implantation. For the purpose of this review, evidence was gathered from electronic literature searches (via PubMed and GoogleScholar), with a particular focus on primary evidence published in the last 5 years.Expert opinion: Ever-expanding research in the field of device therapy has armed physicians with more tools than ever to treat dyssynchronous HF. Newer developments, such as artificial intelligence (AI) guided device programming and conduction system pacing (CSP) are particularly exciting, and we will discuss how they could eventually lead to truly personalized care by maximizing outcomes from CRT.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11716670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of cardiac function using echocardiography in childhood-onset systemic lupus erythematosus patients treated with hydroxychloroquine. 超声心动图评价羟基氯喹治疗的儿童期系统性红斑狼疮患者的心功能。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-12-21 DOI: 10.1080/14779072.2024.2445800

Seher Sener, Yusuf Ziya Sener, Ezgi Deniz Batu, Ilker Ertugrul, Ozge Basaran, Yelda Bilginer, Tevfik Karagoz, Seza Ozen

{"title":"Evaluation of cardiac function using echocardiography in childhood-onset systemic lupus erythematosus patients treated with hydroxychloroquine.","authors":"Seher Sener, Yusuf Ziya Sener, Ezgi Deniz Batu, Ilker Ertugrul, Ozge Basaran, Yelda Bilginer, Tevfik Karagoz, Seza Ozen","doi":"10.1080/14779072.2024.2445800","DOIUrl":"10.1080/14779072.2024.2445800","url":null,"abstract":"Background: This study aimed to evaluate the effects of hydroxychloroquine on cardiac functions and left ventricular mass in patients with childhood-onset systemic lupus erythematosus (cSLE).Research design and methods: Fifty patients with cSLE undergoing treatment with hydroxychloroquine underwent echocardiographic evaluation. All patients exhibited negative disease activity markers and were clinically in remission.Results: The median duration of hydroxychloroquine exposure was 7.1 (5.2-9.5) years, with a median cumulative dose of 784.8 (509.5-3437.6) grams. No correlation was identified between the parameters of left ventricular ejection fraction, left ventricular mass index and geometry, and cumulative hydroxychloroquine dose (p = 0.245, p = 0.094, p = 0.146, respectively). Furthermore, no significant correlation was identified between the cumulative dose of hydroxychloroquine and diastolic cardiac parameters (all p > 0.05). A comparison of the patients who received a cumulative dose of hydroxychloroquine below the median dose (the low-dose group) with those who received a higher dose (the high-dose group) revealed no significant differences in the echocardiographic parameters (all p > 0.05).Conclusions: The findings of this study indicate that chronic hydroxychloroquine use in patients with cSLE does not result in adverse changes in left ventricular mass or impairment of cardiac functions. However, these patients should undergo regular evaluation to monitor for the potential development of cardiotoxicity.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Better blood pressure control with the nanoformulation of antihypertensive drugs. 纳米降压药能更好地控制血压。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-12-09 DOI: 10.1080/14779072.2024.2438813

Steven G Chrysant

{"title":"Better blood pressure control with the nanoformulation of antihypertensive drugs.","authors":"Steven G Chrysant","doi":"10.1080/14779072.2024.2438813","DOIUrl":"10.1080/14779072.2024.2438813","url":null,"abstract":"Introduction: Hypertension is very common and a major risk factor for cardiovascular disease, heart failure, chronic kidney disease, strokes, and death. However, at present only 14% of patients of developing countries have their blood pressure (BP) well controlled. The causes for the failure to control the BP are multiple and one of them could be the formulation of antihypertensive drugs.Areas covered: The recent development of nanotechnology by incorporating the drugs into nanoparticles is a new promising field of nanomedicine and preliminary studies have shown this nanoformulation to be more effective in the treatment of hypertension than the existing drug formulations. Another recent development is the nanoformulation of genes used for the treatment of hypertension and cardiovascular diseases. For current information, a Medline search was conducted between 2017 and 2024 and 36 pertinent papers were selected.Expert opinion: The nanoformulations of drugs help achieve better drug concentrations, improve drug stability, low solubility, short half life, oral bioavailability, narrow therapeutic index, and poor pharmacokinetic and pharmacodynamic profiles, and decrease the adverse effects of antihypertensive drugs. Also, the nanoformulation of genes for the treatment of hypertension has been shown in preliminary studies to be effective, but more research is needed.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0